• Nelfinavir
  • Nelfinavir mesylate (Viracept, formerly AG1343) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. (wikipedia.org)
  • Treating Patients
  • This phase II trial studies how well lenvatinib mesylate works with pembrolizumab in treating patients with gastric or gastroesophageal cancer that has spread to other places in the body or has come back. (cancer.gov)
  • This phase I trial studies the side effects and best dose of capecitabine when given together with lenvatinib mesylate and external beam radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. (cancer.gov)
  • This phase I trial studies the side effects and best dose of lenvatinib mesylate when given together with paclitaxel in treating patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer that has come back or grown. (cancer.gov)
  • salt
  • The chemical name is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide mesylate salt. (wikipedia.org)
  • stop the growth
  • Lenvatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. (cancer.gov)
  • Lenvatinib mesylate may stop the growth of tumor cells by blocking a protein needed for cell growth and may block the growth of new blood vessels necessary for tumor growth. (cancer.gov)
  • Giving
  • Giving capecitabine, lenvatinib mesylate, and external beam radiation therapy may kill more tumor cells. (cancer.gov)